Ameya Rejeev Kirtane, Ph.D.
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Drug Delivery Systems | 16 | 2024 | 2226 | 1.860 |
Why?
|
| Drug Carriers | 6 | 2021 | 706 | 1.390 |
Why?
|
| Nanoparticles | 9 | 2023 | 1959 | 1.020 |
Why?
|
| Nanotechnology | 3 | 2021 | 714 | 0.870 |
Why?
|
| Oils | 1 | 2022 | 56 | 0.800 |
Why?
|
| Food | 2 | 2022 | 774 | 0.690 |
Why?
|
| Phenanthrenes | 2 | 2017 | 66 | 0.640 |
Why?
|
| Laurates | 1 | 2017 | 7 | 0.580 |
Why?
|
| Monoglycerides | 1 | 2017 | 10 | 0.580 |
Why?
|
| Chemistry, Pharmaceutical | 2 | 2015 | 274 | 0.570 |
Why?
|
| Contraceptives, Oral | 1 | 2019 | 554 | 0.570 |
Why?
|
| Vaginal Creams, Foams, and Jellies | 1 | 2017 | 62 | 0.560 |
Why?
|
| Tetrahydroisoquinolines | 1 | 2015 | 81 | 0.490 |
Why?
|
| Heterocyclic Compounds, 3-Ring | 1 | 2018 | 287 | 0.490 |
Why?
|
| Vaccines | 1 | 2023 | 844 | 0.480 |
Why?
|
| Fibrin | 1 | 2017 | 507 | 0.460 |
Why?
|
| Albumins | 1 | 2017 | 575 | 0.460 |
Why?
|
| Nanomedicine | 1 | 2017 | 290 | 0.460 |
Why?
|
| Melanoma, Experimental | 1 | 2017 | 560 | 0.440 |
Why?
|
| Swine | 10 | 2024 | 5915 | 0.410 |
Why?
|
| Polymers | 4 | 2020 | 1617 | 0.410 |
Why?
|
| Communicable Diseases | 1 | 2021 | 875 | 0.410 |
Why?
|
| Pyridones | 1 | 2018 | 809 | 0.400 |
Why?
|
| Gastrointestinal Tract | 5 | 2023 | 833 | 0.400 |
Why?
|
| Capillary Permeability | 1 | 2015 | 773 | 0.370 |
Why?
|
| Anti-HIV Agents | 2 | 2018 | 4527 | 0.370 |
Why?
|
| Tissue Plasminogen Activator | 1 | 2017 | 1164 | 0.370 |
Why?
|
| Luminescent Proteins | 1 | 2013 | 837 | 0.360 |
Why?
|
| Dosage Forms | 3 | 2019 | 56 | 0.350 |
Why?
|
| Paclitaxel | 2 | 2017 | 1732 | 0.340 |
Why?
|
| Cyanides | 2 | 2020 | 82 | 0.330 |
Why?
|
| Transfection | 2 | 2014 | 5774 | 0.320 |
Why?
|
| Guanidines | 2 | 2020 | 194 | 0.310 |
Why?
|
| Antiretroviral Therapy, Highly Active | 1 | 2016 | 1897 | 0.300 |
Why?
|
| Fibrinolytic Agents | 1 | 2017 | 2084 | 0.280 |
Why?
|
| Administration, Oral | 7 | 2019 | 4021 | 0.280 |
Why?
|
| Delayed-Action Preparations | 4 | 2020 | 962 | 0.280 |
Why?
|
| Anti-Retroviral Agents | 1 | 2016 | 1784 | 0.280 |
Why?
|
| Lung Neoplasms | 5 | 2017 | 13382 | 0.260 |
Why?
|
| Animals | 30 | 2024 | 168467 | 0.240 |
Why?
|
| Antineoplastic Agents | 4 | 2016 | 13642 | 0.240 |
Why?
|
| Nanocapsules | 2 | 2016 | 94 | 0.240 |
Why?
|
| Antiviral Agents | 1 | 2017 | 3060 | 0.230 |
Why?
|
| Drug Evaluation, Preclinical | 3 | 2021 | 1334 | 0.230 |
Why?
|
| Excipients | 2 | 2021 | 98 | 0.220 |
Why?
|
| Xenograft Model Antitumor Assays | 5 | 2021 | 3603 | 0.210 |
Why?
|
| Adhesives | 1 | 2023 | 66 | 0.210 |
Why?
|
| Mucous Membrane | 2 | 2023 | 659 | 0.210 |
Why?
|
| Neoplasms | 4 | 2016 | 22173 | 0.200 |
Why?
|
| Models, Biological | 2 | 2016 | 9469 | 0.200 |
Why?
|
| Gels | 1 | 2022 | 420 | 0.180 |
Why?
|
| Vaccines, Synthetic | 1 | 2023 | 616 | 0.180 |
Why?
|
| Nicotinamide Phosphoribosyltransferase | 1 | 2020 | 83 | 0.180 |
Why?
|
| Diterpenes | 2 | 2020 | 171 | 0.170 |
Why?
|
| Immunity, Mucosal | 1 | 2023 | 483 | 0.170 |
Why?
|
| Glucuronides | 1 | 2019 | 20 | 0.170 |
Why?
|
| Levonorgestrel | 1 | 2019 | 74 | 0.170 |
Why?
|
| Pharmaceutical Preparations | 4 | 2024 | 1089 | 0.170 |
Why?
|
| Drug Interactions | 2 | 2024 | 1416 | 0.170 |
Why?
|
| Fluorouracil | 1 | 2024 | 1642 | 0.160 |
Why?
|
| Water | 2 | 2022 | 1411 | 0.150 |
Why?
|
| Tumor Cells, Cultured | 2 | 2017 | 6132 | 0.150 |
Why?
|
| Drug Resistance, Neoplasm | 1 | 2013 | 5305 | 0.150 |
Why?
|
| Curcumin | 1 | 2019 | 98 | 0.150 |
Why?
|
| Intestine, Small | 2 | 2023 | 1206 | 0.150 |
Why?
|
| Stomach | 2 | 2019 | 696 | 0.140 |
Why?
|
| Radiation Protection | 1 | 2021 | 424 | 0.140 |
Why?
|
| Administration, Intravaginal | 1 | 2017 | 150 | 0.140 |
Why?
|
| Biological Availability | 4 | 2024 | 390 | 0.140 |
Why?
|
| Contraceptive Devices, Female | 1 | 2016 | 40 | 0.140 |
Why?
|
| NAD | 1 | 2020 | 614 | 0.130 |
Why?
|
| Intestines | 2 | 2024 | 1909 | 0.130 |
Why?
|
| Drug Design | 3 | 2021 | 1048 | 0.130 |
Why?
|
| Neoplastic Cells, Circulating | 1 | 2023 | 946 | 0.130 |
Why?
|
| Lignans | 1 | 2016 | 84 | 0.130 |
Why?
|
| Rheology | 1 | 2017 | 347 | 0.130 |
Why?
|
| Mouth Neoplasms | 1 | 2021 | 596 | 0.130 |
Why?
|
| Anopheles | 1 | 2018 | 192 | 0.130 |
Why?
|
| Oxazines | 1 | 2018 | 350 | 0.130 |
Why?
|
| Fibrinolysis | 1 | 2017 | 332 | 0.130 |
Why?
|
| High-Throughput Screening Assays | 1 | 2021 | 934 | 0.120 |
Why?
|
| Biological Transport | 3 | 2014 | 2091 | 0.120 |
Why?
|
| Technology, Pharmaceutical | 1 | 2015 | 84 | 0.120 |
Why?
|
| Gastric Mucosa | 1 | 2017 | 604 | 0.120 |
Why?
|
| Porosity | 1 | 2015 | 349 | 0.110 |
Why?
|
| Surface-Active Agents | 1 | 2014 | 150 | 0.110 |
Why?
|
| Cytokines | 2 | 2020 | 7396 | 0.110 |
Why?
|
| Particle Size | 2 | 2015 | 1648 | 0.110 |
Why?
|
| Radiation Injuries | 1 | 2021 | 1189 | 0.110 |
Why?
|
| Humans | 29 | 2024 | 761572 | 0.110 |
Why?
|
| Antineoplastic Agents, Alkylating | 1 | 2017 | 617 | 0.110 |
Why?
|
| Solubility | 1 | 2015 | 1091 | 0.110 |
Why?
|
| Mice, Nude | 2 | 2019 | 3614 | 0.100 |
Why?
|
| Anticarcinogenic Agents | 1 | 2014 | 250 | 0.100 |
Why?
|
| Simian Acquired Immunodeficiency Syndrome | 1 | 2017 | 541 | 0.100 |
Why?
|
| Extracellular Matrix Proteins | 1 | 2017 | 829 | 0.100 |
Why?
|
| Biocompatible Materials | 2 | 2019 | 1685 | 0.100 |
Why?
|
| Antineoplastic Agents, Phytogenic | 1 | 2016 | 621 | 0.100 |
Why?
|
| Isocitrate Dehydrogenase | 1 | 2018 | 938 | 0.100 |
Why?
|
| Simian immunodeficiency virus | 1 | 2017 | 809 | 0.100 |
Why?
|
| Hydrogels | 1 | 2017 | 720 | 0.100 |
Why?
|
| Drug Administration Schedule | 1 | 2019 | 4853 | 0.100 |
Why?
|
| Vagina | 1 | 2017 | 838 | 0.100 |
Why?
|
| Biphenyl Compounds | 1 | 2016 | 1007 | 0.090 |
Why?
|
| Mice | 10 | 2024 | 81533 | 0.090 |
Why?
|
| Vaccination | 1 | 2023 | 3384 | 0.090 |
Why?
|
| Antimalarials | 1 | 2018 | 907 | 0.090 |
Why?
|
| RNA, Messenger | 2 | 2023 | 12794 | 0.090 |
Why?
|
| Macaca mulatta | 1 | 2017 | 2329 | 0.090 |
Why?
|
| Carcinoma, Hepatocellular | 1 | 2023 | 2297 | 0.090 |
Why?
|
| Malaria | 1 | 2018 | 1227 | 0.080 |
Why?
|
| Brain Neoplasms | 2 | 2020 | 9031 | 0.080 |
Why?
|
| Tumor Microenvironment | 1 | 2020 | 3877 | 0.070 |
Why?
|
| Forecasting | 1 | 2016 | 2928 | 0.070 |
Why?
|
| Patient Compliance | 1 | 2018 | 2690 | 0.070 |
Why?
|
| Piperazines | 1 | 2018 | 2523 | 0.070 |
Why?
|
| Liver Neoplasms | 1 | 2023 | 4319 | 0.070 |
Why?
|
| Molecular Targeted Therapy | 1 | 2018 | 2811 | 0.070 |
Why?
|
| Neoplastic Stem Cells | 1 | 2014 | 1349 | 0.070 |
Why?
|
| Cell Line, Tumor | 6 | 2023 | 16986 | 0.070 |
Why?
|
| Indoles | 1 | 2014 | 1833 | 0.070 |
Why?
|
| Neoplasm Proteins | 1 | 2018 | 3617 | 0.070 |
Why?
|
| Hexuronic Acids | 2 | 2017 | 145 | 0.070 |
Why?
|
| Glucuronic Acid | 2 | 2017 | 150 | 0.070 |
Why?
|
| Models, Theoretical | 1 | 2018 | 3575 | 0.060 |
Why?
|
| Nitrosamines | 2 | 2016 | 87 | 0.060 |
Why?
|
| Glioblastoma | 1 | 2020 | 3482 | 0.060 |
Why?
|
| Biological Assay | 2 | 2020 | 626 | 0.060 |
Why?
|
| Folic Acid | 1 | 2012 | 1323 | 0.060 |
Why?
|
| Rabbits | 2 | 2024 | 4772 | 0.060 |
Why?
|
| Alginates | 2 | 2017 | 248 | 0.060 |
Why?
|
| Tissue Distribution | 2 | 2021 | 2264 | 0.060 |
Why?
|
| Female | 11 | 2021 | 392686 | 0.060 |
Why?
|
| Genotype | 1 | 2018 | 12990 | 0.060 |
Why?
|
| Diffusion | 2 | 2016 | 814 | 0.060 |
Why?
|
| Glioma | 1 | 2018 | 3455 | 0.050 |
Why?
|
| Neovascularization, Pathologic | 1 | 2013 | 2644 | 0.050 |
Why?
|
| Cell Survival | 3 | 2017 | 5791 | 0.050 |
Why?
|
| Taurocholic Acid | 1 | 2021 | 43 | 0.050 |
Why?
|
| Glycyrrhizic Acid | 1 | 2021 | 11 | 0.050 |
Why?
|
| Skin Absorption | 1 | 2021 | 94 | 0.050 |
Why?
|
| Mice, Inbred BALB C | 2 | 2020 | 6214 | 0.040 |
Why?
|
| Antimetabolites, Antineoplastic | 1 | 2024 | 646 | 0.040 |
Why?
|
| HIV Infections | 2 | 2017 | 17352 | 0.040 |
Why?
|
| Tretinoin | 1 | 2023 | 519 | 0.040 |
Why?
|
| Injections, Intralesional | 1 | 2020 | 280 | 0.040 |
Why?
|
| Glucuronosyltransferase | 1 | 2020 | 132 | 0.040 |
Why?
|
| Child, Preschool | 1 | 2022 | 42230 | 0.040 |
Why?
|
| Infusions, Intravenous | 1 | 2024 | 2218 | 0.040 |
Why?
|
| Hep G2 Cells | 1 | 2020 | 379 | 0.040 |
Why?
|
| Organs at Risk | 1 | 2021 | 359 | 0.040 |
Why?
|
| Acrylamides | 1 | 2020 | 260 | 0.040 |
Why?
|
| Veterinary Medicine | 1 | 2018 | 21 | 0.040 |
Why?
|
| Mice, Inbred Strains | 1 | 2021 | 1762 | 0.040 |
Why?
|
| Mice, Inbred C57BL | 1 | 2017 | 22172 | 0.040 |
Why?
|
| MicroRNAs | 1 | 2014 | 3816 | 0.040 |
Why?
|
| Candida albicans | 1 | 2021 | 372 | 0.040 |
Why?
|
| Signal Transduction | 2 | 2020 | 23447 | 0.040 |
Why?
|
| Glucuronidase | 1 | 2019 | 202 | 0.040 |
Why?
|
| RNA, Small Interfering | 2 | 2017 | 3430 | 0.040 |
Why?
|
| Prodrugs | 1 | 2019 | 261 | 0.040 |
Why?
|
| Magnolia | 1 | 2016 | 3 | 0.040 |
Why?
|
| Acrylic Resins | 1 | 2017 | 135 | 0.040 |
Why?
|
| Cell Movement | 2 | 2020 | 5205 | 0.030 |
Why?
|
| Epoxy Compounds | 1 | 2017 | 137 | 0.030 |
Why?
|
| Pancreatic Neoplasms | 1 | 2014 | 5369 | 0.030 |
Why?
|
| Epithelium | 1 | 2020 | 1603 | 0.030 |
Why?
|
| Computer Simulation | 2 | 2021 | 6241 | 0.030 |
Why?
|
| Dioctyl Sulfosuccinic Acid | 1 | 2014 | 8 | 0.030 |
Why?
|
| Cytochrome P-450 CYP1A1 | 1 | 2014 | 90 | 0.030 |
Why?
|
| Models, Chemical | 1 | 2016 | 611 | 0.030 |
Why?
|
| Singlet Oxygen | 1 | 2014 | 58 | 0.030 |
Why?
|
| Methylene Blue | 1 | 2014 | 155 | 0.030 |
Why?
|
| Child | 1 | 2022 | 80156 | 0.030 |
Why?
|
| Materials Testing | 1 | 2017 | 863 | 0.030 |
Why?
|
| Mutation | 1 | 2018 | 30054 | 0.030 |
Why?
|
| Mice, SCID | 1 | 2018 | 2626 | 0.030 |
Why?
|
| Drug Compounding | 1 | 2014 | 246 | 0.030 |
Why?
|
| Esophagus | 1 | 2019 | 1033 | 0.030 |
Why?
|
| Rats | 2 | 2021 | 23741 | 0.030 |
Why?
|
| Administration, Intranasal | 1 | 2014 | 477 | 0.030 |
Why?
|
| Plant Extracts | 1 | 2016 | 498 | 0.030 |
Why?
|
| Autophagy | 1 | 2020 | 1326 | 0.030 |
Why?
|
| Bronchi | 1 | 2016 | 845 | 0.030 |
Why?
|
| Absorption | 1 | 2012 | 242 | 0.030 |
Why?
|
| Carcinogens | 1 | 2014 | 452 | 0.030 |
Why?
|
| Temperature | 1 | 2019 | 2226 | 0.030 |
Why?
|
| Piperidines | 1 | 2020 | 1656 | 0.020 |
Why?
|
| Caco-2 Cells | 1 | 2012 | 364 | 0.020 |
Why?
|
| United States Food and Drug Administration | 1 | 2020 | 1664 | 0.020 |
Why?
|
| Up-Regulation | 1 | 2020 | 4124 | 0.020 |
Why?
|
| Cell Proliferation | 2 | 2017 | 10448 | 0.020 |
Why?
|
| Polyglycolic Acid | 1 | 2012 | 406 | 0.020 |
Why?
|
| Liposomes | 1 | 2014 | 784 | 0.020 |
Why?
|
| Apoptosis | 2 | 2017 | 9489 | 0.020 |
Why?
|
| Kinetics | 1 | 2018 | 6374 | 0.020 |
Why?
|
| Gene Silencing | 1 | 2017 | 1509 | 0.020 |
Why?
|
| Permeability | 1 | 2012 | 723 | 0.020 |
Why?
|
| Photosensitizing Agents | 1 | 2014 | 623 | 0.020 |
Why?
|
| B-Lymphocytes | 1 | 2023 | 4758 | 0.020 |
Why?
|
| Rats, Sprague-Dawley | 1 | 2021 | 8181 | 0.020 |
Why?
|
| Gene Expression Regulation, Enzymologic | 1 | 2014 | 1171 | 0.020 |
Why?
|
| Disease Models, Animal | 2 | 2021 | 18253 | 0.020 |
Why?
|
| Genes, Tumor Suppressor | 1 | 2014 | 1062 | 0.020 |
Why?
|
| Anti-Inflammatory Agents, Non-Steroidal | 1 | 2018 | 2273 | 0.020 |
Why?
|
| Cell Cycle | 1 | 2016 | 2932 | 0.020 |
Why?
|
| Photochemotherapy | 1 | 2014 | 823 | 0.020 |
Why?
|
| CD4-Positive T-Lymphocytes | 1 | 2020 | 4369 | 0.020 |
Why?
|
| Lactic Acid | 1 | 2012 | 1139 | 0.020 |
Why?
|
| CD8-Positive T-Lymphocytes | 1 | 2020 | 4580 | 0.020 |
Why?
|
| Macrophages | 1 | 2020 | 5769 | 0.020 |
Why?
|
| Membrane Proteins | 1 | 2020 | 7858 | 0.010 |
Why?
|
| Feasibility Studies | 1 | 2014 | 5247 | 0.010 |
Why?
|
| Cells, Cultured | 1 | 2017 | 18965 | 0.010 |
Why?
|
| Intestinal Mucosa | 1 | 2012 | 3032 | 0.010 |
Why?
|
| Epithelial Cells | 1 | 2012 | 3677 | 0.010 |
Why?
|
| Disease Progression | 1 | 2016 | 13510 | 0.010 |
Why?
|
| Tomography, X-Ray Computed | 1 | 2021 | 20571 | 0.010 |
Why?
|
| Algorithms | 1 | 2017 | 14032 | 0.010 |
Why?
|
| Lung | 1 | 2014 | 10002 | 0.010 |
Why?
|
| Male | 3 | 2018 | 360842 | 0.010 |
Why?
|
| United States | 1 | 2020 | 72335 | 0.010 |
Why?
|
| Breast Neoplasms | 1 | 2019 | 21017 | 0.010 |
Why?
|